- Home
- PNW vs MRNA Comparison
PNW vs MRNA Comparison
Compare PNW & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNW | MRNA |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PNW | MRNA |
|---|---|---|
| Price | $87.50 | $35.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | ★ $95.73 | $33.25 |
| AVG Volume (30 Days) | 1.1M | ★ 10.5M |
| Earning Date | 02-24-2026 | 02-13-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $5,307,180,000.00 | $2,232,000,000.00 |
| Revenue This Year | $4.96 | N/A |
| Revenue Next Year | $4.02 | $2.17 |
| P/E Ratio | $18.15 | ★ N/A |
| Revenue Growth | ★ 5.70 | N/A |
| 52 Week Low | $81.47 | $22.28 |
| 52 Week High | $96.50 | $48.92 |
Technical Indicators
Market Signals| Indicator | PNW | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 69.65 |
| Support Level | $86.33 | $29.06 |
| Resistance Level | $89.49 | $31.25 |
| Average True Range (ATR) | 1.17 | 1.89 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 34.04 | 85.01 |
Price Performance
Historical ComparisonAbout PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.